Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Refractory Epilepsy
NCT ID: NCT02602899
Last Updated: 2016-12-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2015-04-30
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PINS Deep Brain Stimulator
Deep Brain Stimulator is on,continuous stimulation to the brain,
PINS'Deep Brain Stimulator device
deep brain stimulation of the PINS'IPG function to anterior nucleus of the thalamus is off in a short time
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PINS'Deep Brain Stimulator device
deep brain stimulation of the PINS'IPG function to anterior nucleus of the thalamus is off in a short time
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* having tried at least two appropriate anti-epileptic drugs (AEDs) tested to tolerance or to blood levels at upper end of the target range of which at least 2 have been tolerated at normal dose.
* at least 6 seizures per month.
* in good health except epilepsy.
* to with normal MMSE score
* patients or his(her) familys could understand this method and sign the informed consent 7）Patients with good compliance and could complete postoperative follow-up
Exclusion Criteria
* the vagus nerve lesion and damage
* tumor, cardiopulmonary anomaly, progressive neurological diseases, asthma，mental disease，peptic ulcer，diabetes Type 1，bad health etc, and other surgical contraindication.
12 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Tiantan Hospital
OTHER
Beijing Pins Medical Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luming Li
Role: STUDY_CHAIR
study principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Luming Li
Role: CONTACT
Phone: +86 010-60736388
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jianguo Zhang, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PINS-013
Identifier Type: -
Identifier Source: org_study_id